{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=11", "query": { "condition": "Follicular Neoplasm", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1364, "total_pages": 137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T11:31:35.799Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00008021", "title": "Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody Lym-1", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody Lym-1", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody Lym-1", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-07", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008021" }, { "nct_id": "NCT00004916", "title": "Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "ifosfamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "teniposide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004916" }, { "nct_id": "NCT01144247", "title": "Cellular Immunotherapy Study for Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliomas", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Mixed Glioma", "Glioblastoma Multiforme", "Malignant Meningioma" ], "interventions": [ { "name": "alloreactive CTL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-07", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-05-27", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01144247" }, { "nct_id": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mantle Cell Lymphoma", "Peripheral T-cell Lymphoma (PTCL)", "Cutaneous T-cell Lymphoma (CTCL)", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Hodgkin Lymphoma", "Waldenstrom Macroglobulinemia", "DLBCL" ], "interventions": [ { "name": "L-Bcl-2 antisense oligonucleotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-11-05", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 5, "location_summary": "Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Valhalla", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072458" }, { "nct_id": "NCT00005988", "title": "Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myeloma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 5, "start_date": "2000-02", "completion_date": "2002-03-08", "has_results": false, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005988" }, { "nct_id": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2004-05", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Lebanon, New Hampshire • Burlington, Vermont", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110149" }, { "nct_id": "NCT03198026", "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Nodal Marginal Zone Lymphoma", "Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Nodal Marginal Zone Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Nodal Marginal Zone Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Indolent Non-hodgkin Lymphoma", "Stage II Splenic Marginal Zone Lymphoma", "Stage III Splenic Marginal Zone Lymphoma", "Stage IV Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-02-20", "completion_date": "2032-02-20", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03198026" }, { "nct_id": "NCT01497184", "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "HSCT", "type": "PROCEDURE" }, { "name": "DLI", "type": "GENETIC" } ], "intervention_types": [ "PROCEDURE", "GENETIC" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 95, "start_date": "2011-12", "completion_date": "2021-03-08", "has_results": false, "last_update_posted_date": "2025-03-13", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497184" }, { "nct_id": "NCT00002552", "title": "Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "perfosfamide", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "syngeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 40, "start_date": "1993-10", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2013-04-09", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002552" }, { "nct_id": "NCT06049485", "title": "Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Follicular Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Power Life Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-10-24T11:31:35.799Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06049485" } ] }